TABLE 2.

Overview of analytic and clinical validation data for common catalytic pancreatic lipase assays in dogs

Assay	Analytic evaluation				Clinical evaluation
	Analytic validation	Measurement in EPI dogs a	Effect of heparinization b	Effect of lipemia, icterus, and/or hemolysis c	Histopathologic reference standard	Clinical reference standard
DGGR lipase	Laboratory: interassay CV <3% and intra‐assay CV ≤14% 69 Linearity: R 2 .98 69 Clinical agreement with Spec cPL k = 0.43‐0.68 69 , 75 ICC = 0.89 50	Median 34 U/L (RI: 20‐94 U/L) Lipase within RI in 33/48 dogs 73	Significant increases in lipase detected postheparinization 74	No significant effect 69	–	Sensitivity: 85.7%‐93.3% 50 , 69 Specificity: 53.3%‐74.3% 50 , 69
v‐LIP‐P	Laboratory: Inter‐ and intra‐assay CV < 5% 77 Clinical agreement with Spec cPL r = .91 79	58% of dogs had lipase concentration within lower 20% of RI (≤32 U/L) 78% of dogs had lipase concentration within lower 25% of RI (≤40 U/L) 78	–	Intralipid administration increases v‐LIP‐P activity Naturally occurring hyperlipidemia had a lesser effect on v‐LIP‐P activity 78 Influenced by hemolysis 78	–	Sensitivity: 100% 45 Specificity: 89.5% 45

^a Dogs with EPI should have negligible serum activities of pancreatic lipase.

^b Heparinization leads to release of lipoprotein lipase and hepatic lipase.

^c Lipemia and icterus are commonly seen in dogs with suspected pancreatitis.